Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809473 | 0.78 | KIF11 (0.53) | RAD52CYP1A2CYP2D6HDAC1HDAC8 | |
| SCHEMBL30869731 | 0.74 | MAPK1 (0.34) | RAD52PRMT5WDR77 | |
| SCHEMBL14808960 | 0.73 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL30869833 | 0.65 | PRMT5 (0.39) | PRMT5WDR77KCNH2 | |
| SCHEMBL14809523 | 0.65 | FPR2 (0.69) | RAD52CYP1A2CYP2D6HDAC6KCNH2 | |
| SCHEMBL30869613 | 0.65 | MAPK1 (0.32) | PRMT5WDR77 | |
| SCHEMBL6974244 | 0.64 | DRD2 (0.55) | PRMT5WDR77KCNH2 | |
| SCHEMBL2951133 | 0.59 | HDAC1 (0.45) | HDAC1HDAC8HDAC6 | |
| SCHEMBL31490924 | 0.58 | HDAC6 (0.41) | CYP1A2CYP2D6HDAC1HDAC8HDAC6 | |
| SCHEMBL6045344 | 0.58 | KDM1A (0.54) | RAD52CYP1A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758403-B1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION INC (US) | 2016-04-27 | — | — | EP | claimed |
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION, INC. | 2014-08-28 | — | — | US | claimed |
| EP-2758403-B1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9187439-B2 | Tricyclic compounds useful as neurogenic and neuroprotective agents | INCEPTION ORION, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187439-B2 | Tricyclic compounds useful as neurogenic and neuroprotective agents | INCEPTION ORION, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187439-B2 | Tricyclic compounds useful as neurogenic and neuroprotective agents | INCEPTION ORION, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION, INC. | 2014-08-28 | — | — | US | disclosed |
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION, INC. | 2014-08-28 | — | — | US | disclosed |
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION, INC. | 2014-08-28 | — | — | US | disclosed |
| WO-2013043744-A2 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION 1, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | BDNF, GAP43, NLN | RAD52 4754/4885NLRP1 4150/4885PRMT5 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.